Nav: Home

Large global range of prices for hepatitis C medicines raises concerns about affordability

May 31, 2016

The prices and affordability of recently developed and highly effective direct-acting antivirals for treating hepatitis C (HCV) vary greatly among countries worldwide, according to a study published this week in PLOS Medicine. Suzanne Hill and colleagues from the World Health Organization undertook an economic analysis of prices for a 12-week course of treatment with sofosbuvir and ledipasvir/sofosbuvir in 30 countries - mostly European as well as Egypt and Mongolia, adjusting for average 2015 exchange rates and purchasing power parity (PPP). While the nominal price based on exchange rates was highest in the US (US$72,765 for a 12-week course of ledipasvir/sofosbuvir), PPP-adjusted prices in Central and Eastern European countries were highest, costing up to 1.63 times as much in Poland (PPP$118,754 for a 12 week course of ledipasvir/sofosbuvir). The researchers went on to calculate the cost of treating the entire HCV infected population in each of the countries studied. Using previous estimates of HCV burden by country, they calculated that it would range from 10.5% of the total pharmaceutical expenditure (TPE) to treat all HCV patients in the Netherlands with the new HCV medications, to 190.5% of the TPE to treat all patients in Poland.

The authors note that their analysis is limited by the accuracy of the estimates of the numbers of people infected and price information that was accessible, and that some actual prices may be lower than the publicly accessible numbers because of confidential discounts. They also note, however, that they only considered the cost of sofosbuvir and ledipasvir/sofosbuvir and did not consider extra costs of treatment such as screening and follow-up. The authors say their analysis illustrates the wide range of affordability worldwide and suggests a need for an updated pricing system: "In order for countries to increase investment and minimise the burden of hepatitis C, governments and industry stakeholders will need to jointly develop and implement fairer pricing frameworks that deliver lower and more affordable prices".

In an accompanying Perspective, Elliot Marseille and James G. Kahn discuss the pricing of these new HCV medications in relation to the high initial cost when HIV anti-retroviral therapy was introduced in the 1990s. Marseille and Kahn compare and contrast the situations, and suggest ways forward such as treating a proportion of cases initially, to spread the upfront cost of HCV treatment over several years while fighting for lower drug prices.
Research Article


The authors received no specific funding for this work.

Competing Interests:

SH is a member of the PLOS Medicine Editorial Board. KTT has been an employee of Deloitte Australia within the past 5 years. Deloitte Australia has provided consulting services to pharmaceutical companies. However, KTT has not been involved in any project directly related to the content of this manuscript that can lead to conflict of interest.


Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. (2016) Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. PLoS Med 13(5): e1002032. doi:10.1371/journal.pmed.1002032

Author Affiliations:

World Health Organization, Geneva, Switzerland

WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Health Economics Department, Gesundheit Österreich, Vienna, Austria


Perspective Article


There was no funding for this work.

Competing Interests:

The authors have declared that no competing interests exist.


Marseille E, Kahn JG (2016) A Revolution in Treatment for Hepatitis C Infection: Mitigating the Budgetary Impact. PLoS Med 13(5): e1002031. doi:10.1371/journal.pmed.1002031

Author Affiliations:

Health Strategies International, Oakland, California, United States of America

Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, San Francisco, California, United States of America



Related Hepatitis Articles:

Hepatitis C increasing among pregnant women
Hepatitis C infections among pregnant women nearly doubled from 2009-2014, likely a consequence of the country's increasing opioid epidemic that is disproportionately affecting rural areas of states including Tennessee and West Virginia.
WHO's Global Hepatitis Report sets baseline to eliminate viral hepatitis by 2030
The World Hepatitis Alliance today welcomes the publication of the first-ever Global Hepatitis Report by the World Health Organization (WHO), which includes new data on the prevalence and global burden of viral hepatitis.
Elimination of viral hepatitis by 2030: What's needed and how do we get there?
This first European Action Plan provides an important driver to aid countries in their fight against viral hepatitis, to which ECDC had the opportunity to contribute directly.
Discovery of new Hepatitis C virus mechanism
Researchers at Osaka University, Japan uncovered the mechanisms that suppress the propagation of the hepatitis C virus with the potential of improving pathological liver conditions.
Is Europe ready to eliminate viral hepatitis?
Currently, Europe records around 57,000 newly diagnosed acute and chronic cases of hepatitis B and C each year.
Why baby boomers need a hepatitis C screening
Hepatitis C affects a disproportionate amount of older Americans, born between 1945 and 1965.
Counterattack of the hepatitis B virus
The hepatitis B virus (HBV) infects liver cells. Drugs are available to treat HBV, but they rarely cure the infection, and so the virus typically returns after the treatment ends.
Hepatitis C tied to increased risk of Parkinson's
The hepatitis C virus may be associated with an increased risk of developing Parkinson's disease, according to a study published in the Dec.
The hepatitis A virus is of animal origin
The hepatitis A virus can trigger acute liver inflammation which generally has a mild course in small children but which can become dangerous in adults.
Modeling the helicase to understand hepatitis C
NS3 is an enzyme specific to the hepatitis C virus.

Related Hepatitis Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".